Priority 1: Revolutionize Medicine
Advance Science
by implementing new knowledge, treatments and clinical approaches that answer the most pressing questions for children in the region.
Revolutionize Medicine
TREAT TO CURE.
DISCOVER TO ERADICATE.
Imagine a life without being able to eat. Or walk. Or breathe without pain. Imagine a life without answers.
We live in a remarkable era of scientific discovery and clinical advancement. Discoveries in pediatric medicine are changing the future of what is possible in healing and managing disease and disorders, particularly in rare conditions requiring complex care. Advancements in targeted cellular and gene therapies, biologics, immunizations, genomic medicine, robotic devices, noninvasive diagnostics, radiological imaging and mobile medicine have all significantly improved the outlook on child health and offered new hope to millions of children.
Core Team Strategies
1
Advance Arkansas Children’s Heart Institute programs through transcatheter procedure expansion, advanced imaging techniques, lifespan care and surgical research.
2
Build leading programs in head and neck surgery and plastics surgery, integrating services and provide pioneering surgical approaches, pain management and wound care.
3
Establish maternal-fetal coordination services to provide a multidisciplinary, multimodality, one-front door solution to prenatal needs and maternal support for moms in the region.
4
Expand pediatric minimally invasive surgery, including laparoscopic, robotic and laser procedures that reduce the need for sedation.
5
Embed behavioral and mental health services in emergency, primary and subspecialty care, to include screening, crisis intervention and short-term counseling with a specific focus on launching virtual health solutions.
6
Deliver newly developed diagnostics and treatments aimed at diagnosing and curing rare, complex and chronic conditions, which includes genomics, gene and cellular therapies and biologics.
LEAD DISCOVERY IN AREAS OF opioid and substance abuse research; nutrition and healthy living; critical care, acute injury and injury prevention; and neurosciences research to advance clinical care and
overall pediatric health.
A Continuous Focus on Academic Discovery, Research and Innovation
Accelerates Our Promise For A Healthier Tomorrow
Every day at Arkansas Children's, clinical leaders and health care professionals make critical decisions concerning the health of infants, children and adolescents. These decisions emanate from knowledge - organized information that is born from research discoveries, evidence-based practices and innovation. Research and innovation are the foundation of generational hope, the promise and the pathway to a cure, a treatment or a broader promise of a healthy life.
CORE RESEARCH AND INNOVATION EFFORTS
ESTABLISH NATIONALLY-LEADING RESEARCH IN OPIOID AND SUBSTANCE USE
to improve care and prevention efforts aimed at dramatically decreasing the negative impacts of misuse and addiction.
ADVANCE NATIONAL LEADING NUTRITION AND HEALTHY LIVING RESEARCH
by implementing targeted interventions and promoting community health to reduce chronic and metabolic diseases and enhance long‑term health across diverse populations.
EXPAND CRITICAL ILLNESS AND INJURY RESEARCH
by leveraging team science, omics, translational and implementation research and community engagement to reduce the incidence and severity of critical illness and injury and improve the outcomes and quality of life.
ENHANCE NEUROSCIENCES RESEARCH
to better understand the functions of the brain and how brain health is impacted by certain conditions and their treatments to create a future where every child thrives cognitively, emotionally and physically.
The Faces Of
Life-Changing Outcomes
Imagine who they will become.
Imagine what they will do.
Imagine how they will impact our community.
Arkansas Children's is ready for the unexpected and the unknown, for the rare, complex and lifethreatening. As we continue to invest in the future of medicine and new, innovative therapies that were merely hope on the horizon a few years ago, we see the impact daily on the children we serve.
Mackenzie
First pediatric patient in Arkansas to go home on an LVAD (Left Ventricular Assist Device).
WESLEY
Wesley was born with Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease. But just before turning 6, Wesley received his single Elevidys infusion at Arkansas Children's thanks to Aravindhan Veerapandiyan, M.D., (known as "Dr. Panda") and a clinical trial providing new hope for an extended high-quality life. Today, the FDA has expanded the approval of this gene therapy to all boys with DMD who are 4 years and older.
JESSE
Jesse White, 11, became the first pediatric patient in Arkansas treated with TZIELD, an FDA-approved drug therapy for delaying the onset of Type 1 diabetes. It requires 14 consecutive days of infusions, and studies show that it gives patients, on average, an extra two years between stages 2 and 3 in their diagnosis. Because of this innovative therapy, kids like Jesse have more time to be kids before their lives change with the need for daily medications.
© 2025 Arkansas Children's.
Política de privacidad
Términos de uso
Resumen
enterprise priorities
Join our team
Dar
1. Revolutionize Medicine
2. Regionalize Care
3. Realize Our Promise
4. Rely on Each Other
5. Remove Barriers
enterprise priorities
© 2025 Arkansas Children's.
Política de privacidad
Términos de uso
Resumen
enterprise priorities
1. Revolutionize Medicine
2. Regionalize Care
3. Realize Our Promise
4. Rely on Each Other
5. Remove Barriers
Join our Team
Dar
Resumen
enterprise priorities
1. Revolutionize Medicine
2. Regionalize Care
3. Realize Our Promise
4. Rely on Each Other
5. Remove Barriers
Join our Team
Dar